faculty

Publications

Conformational perturbation of SARS-CoV-2 spike protein using N-acetyl cysteine: an exploration of probable mechanism of action to combat COVID-19.

Groups and Associations Debnath, Utsab; Mitra, Amrita; Dewaker, Varun; Prabhakar, Yenamandra S.; Tadala, Raghu; Krishnan, Kiran; Wagh, Padmakar; Velusamy, Umashankar; Baliyan, Aastha; Kurpad, Anura V.; Bhattacharyya, Parthasarathi; Mandal, Amit Kumar
Journal of biomolecular structure & dynamics 2024

The infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) resulted in a pandemic with huge death toll and economic  consequences. The virus attaches itself to the human epithelial cells through  noncovalent bonding of its spike protein with the angiotensin-converting enzyme-2  (ACE2) receptor on the host cell. Based on in silico studies we hypothesized that  perturbing the functionally active conformation of spike protein through the  reduction of its solvent accessible disulfide bonds, thereby disintegrating its  structural architecture, may be a feasible strategy to prevent infection by  reducing the binding affinity towards ACE2 enzyme. Proteomics data showed that  N-acetyl cysteine (NAC), an antioxidant and mucolytic agent been widely in use in  clinical medicine, forms covalent conjugates with solvent accessible cysteine  residues of spike protein that were disulfide bonded in the native state.  Further, in silico analysis indicated that the presence of the selective covalent  conjugation of NAC with Cys525 perturbed the stereo specific orientations of the  interacting key residues of spike protein that resulted in threefold weakening in  the binding affinity of spike protein with ACE2 receptor. Interestingly, almost  all SARS-CoV-2 variants conserved cystine residues in the spike protein. Our  finding results possibly provides a molecular basis for identifying NAC and/or  its analogues for targeting Cys-525 of the viral spike protein as fusion  inhibitor and exploring in vivo pharmaco-preventive and its therapeutic potential  activity for COVID-19 disease. However, in-vitro assay and animal model-based  experiment are required to validate the probable mechanism of action.Communicated  by Ramaswamy H. Sarma.